FILTER
LATEST INTERVIEWS
Fernando Porcile & Eduardo Covarrubias
EXECUTIVE CHAIRMAN & DIRECTOR, LOS ANDES COPPER
Los Andes Copper updates GBR on progress at its Vizcachitas project in Chile.
Vivek Sharma
CEO, ADARE PHARMA SOLUTIONS
Adare Pharma Solutions explains how it is expanding its range as a leading technology-driven CDMO.
John Huang
CEO, THEWELL BIOSCIENCE
TheWell Bioscience is a biomedical technology company providing innovative 3D cell platforms for drug discovery, cell therapy and personalized medicine.
Antonio Samaniego
DIRECTOR, SRK CONSULTING
SRK Consulting explains the current conditions for mining in Peru.
Rik De Buyserie
COUNTRY MANAGER, ENGIE IN PERU & CEO, ENGIE ENERGÍA PERÚ
ENGIE Energía Perú explains how renewable energy is increasingly being adopted by Peru’s mines.
Jonatan Julien
MINISTER OF ENERGY AND NATURAL RESOURCES, GOVERNMENT OF QUÉBEC
Québec’s Minister of Energy and Natural Resources explains how the province will play a crucial role in the global energy transition.
Cosimo Lenti
BUSINESS DIRECTOR, DIATHEVA
Diatheva promotes biotechnological innovation by providing high-value customized diagnostic kits and solutions.
Gilda D'Incerti
CEO AND FOUNDER, PQE GROUP
PQE Group explains its imperative to expand rapidly apace with the global life science industry.
Peter Steenkamp
CEO, HARMONY
Harmony explains why South African miners are finally feeling more confident.
Ralf Hennecke
GENERAL MANAGER - TECHNOLOGY AND MARKETING, BME
BME explains how it is helping South African mines to transition towards smart mining.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
